DaVita HealthCare Partners Inc (DVA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $10.98B
Last updated: Nov 17, 2026 at 11:04 AM ET
DaVita HealthCare Partners Inc (DVA) Financials: Revenue, Profit and Cash Flow
DaVita HealthCare Partners reported revenue of $13.64B for the fiscal year ended Dec 31, 2025, up 6.5% from the year before. That year, net income was $1.08B with a net margin of 7.9%, operating cash flow was $1.89B and free cash flow was $1.31B. The quarter ended Sep 30, 2026 had revenue of $3.58B and net income of $269.39M.
Revenue and Margins
The operating margin was 15.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $11.14B, a compound annual rate of 2.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $13.64B | +6.5% | 32.2% | 15.0% | 7.9% |
| Dec 2024 | $12.82B | +5.6% | 32.9% | 16.3% | 9.8% |
| Dec 2023 | $12.14B | +4.6% | 31.5% | 13.2% | 7.9% |
| Dec 2022 | $11.61B | -0.1% | 29.3% | 11.5% | 6.7% |
| Dec 2021 | $11.62B | +0.6% | 31.4% | 15.5% | 10.4% |
| Dec 2020 | $11.55B | +1.4% | 30.8% | 14.7% | 8.6% |
| Dec 2019 | $11.39B | -0.1% | 30.5% | 14.4% | 9.0% |
| Dec 2018 | $11.40B | +0.4% | 28.1% | 13.4% | 2.9% |
| Dec 2017 | $11.36B | +2.0% | 28.5% | 16.0% | 7.3% |
| Dec 2016 | $11.14B | N/A | 29.3% | 18.2% | 9.3% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 13.6% from the year before. In the quarter ended Sep 2026, net income rose 12.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.64B | $12.82B | $12.14B | $11.61B | $11.62B | $11.55B | $11.39B | $11.40B | $11.36B | $11.14B |
| Cost of revenue | $9.24B | $8.60B | $8.32B | $8.21B | $7.97B | $7.99B | $7.91B | $8.20B | $8.13B | $7.87B |
| Gross profit | $4.40B | $4.22B | $3.82B | $3.40B | $3.65B | $3.56B | $3.47B | $3.21B | $3.24B | $3.26B |
| Operating income | $2.04B | $2.09B | $1.60B | $1.34B | $1.80B | $1.69B | $1.64B | $1.53B | $1.81B | $2.03B |
| Net income | $1.08B | $1.25B | $956.98M | $781.64M | $1.21B | $994.68M | $1.02B | $333.04M | $830.55M | $1.03B |
| EBITDA | $2.66B | $2.74B | $2.33B | $2.06B | $2.48B | $2.34B | $2.29B | $2.13B | $2.61B | $2.76B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.58B | $3.55B | $3.42B | $3.62B | $3.42B | $3.38B | $3.22B | $3.29B | $3.26B | $3.19B | $3.07B | $3.15B |
| Gross profit | $1.13B | $1.16B | $1.07B | $1.21B | $1.09B | $1.12B | $983.87M | $1.07B | $1.11B | $1.04B | $991.58M | $1.01B |
| Operating income | $499.25M | $579.00M | $481.89M | $561.07M | $505.77M | $537.84M | $438.94M | $565.36M | $534.88M | $506.40M | $483.85M | $389.91M |
| Net income | $269.39M | $343.22M | $275.04M | $331.03M | $240.25M | $275.22M | $232.22M | $349.25M | $295.76M | $299.75M | $305.98M | $230.57M |
Balance Sheet
As of Dec 2025, total debt of $10.27B exceeded cash and equivalents by $9.60B. Shareholder equity was negative, at -$651.08M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $17.48B | $17.29B | $16.89B | $16.93B | $17.12B | $16.99B | $17.31B | $19.11B | $18.97B | $18.76B |
| Current assets | $4.06B | $3.75B | $3.14B | $3.16B | $3.17B | $3.15B | $3.69B | $8.42B | $8.77B | $3.99B |
| Cash and equivalents | $676.44M | $794.93M | $380.06M | $244.09M | $461.90M | $324.96M | $1.10B | $323.04M | $508.23M | $674.78M |
| Total liabilities | $16.32B | $15.19B | $14.15B | $14.70B | $14.75B | $14.09B | $13.81B | $14.08B | $13.08B | $12.93B |
| Short-term debt | $109.20M | $270.87M | $123.30M | $231.40M | $179.03M | $168.54M | $130.71M | $1.93B | $178.21M | $160.26M |
| Long-term debt | $10.16B | $9.18B | $8.27B | $8.69B | $8.73B | $7.92B | $7.98B | $8.17B | $9.16B | $8.94B |
| Shareholder equity | -$651.08M | $121.12M | $1.06B | $712.33M | $755.51M | $1.38B | $2.13B | $3.70B | $4.69B | $4.65B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $17.82B | $17.71B | $17.50B | $17.48B | $17.56B | $17.49B | $17.12B | $17.29B | $17.50B | $17.03B | $17.43B | $17.62B |
| Total liabilities | $16.69B | $16.63B | $16.45B | $16.32B | $16.22B | $15.94B | $15.46B | $15.19B | $15.28B | $14.60B | $14.79B | $14.88B |
| Cash and equivalents | $495.63M | $668.96M | $644.24M | $757.75M | $705.96M | $708.42M | $438.78M | $794.93M | $1.07B | $416.49M | $345.13M | $464.63M |
| Shareholder equity | -$591.09M | -$765.10M | -$755.50M | $1.16B | -$571.87M | -$369.63M | -$267.10M | $2.09B | $386.71M | $632.90M | $926.00M | $2.74B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 69.3% of operating cash flow. Dividends and share repurchases together came to 126.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.89B | $2.02B | $2.06B | $1.56B | $1.93B | $1.98B | $2.07B | $1.77B | $1.91B | $1.97B |
| Capital expenditures | $575.86M | $555.44M | $567.99M | $603.43M | $641.47M | $674.54M | $766.55M | $987.14M | $905.25M | $829.10M |
| Free cash flow | $1.31B | $1.47B | $1.49B | $961.14M | $1.29B | $1.30B | $1.31B | $784.50M | $1.01B | $1.14B |
| Dividends paid | $350.27M | $391.00M | $293.49M | $288.72M | $264.14M | $260.95M | $301.14M | $224.52M | $216.82M | $213.91M |
| Share repurchases | $1.31B | $1.39B | $272.22M | $802.23M | $1.54B | $1.46B | $2.38B | $1.16B | $802.95M | $1.10B |
| Investing cash flow | -$654.95M | -$771.43M | -$771.80M | -$630.35M | -$784.73M | -$825.37M | $3.00B | -$1.01B | -$1.36B | -$1.20B |
| Financing cash flow | -$1.37B | -$816.94M | -$1.17B | -$1.12B | -$1.08B | -$1.85B | -$4.70B | -$625.35M | -$766.26M | -$1.35B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $518.83M | $490.07M | $320.83M | $540.73M | $841.53M | $324.24M | $180.01M | $547.63M | $810.40M | $798.85M | -$134.84M | $485.20M |
| Capital expenditures | $159.49M | $169.82M | $102.02M | $145.43M | $166.09M | $121.09M | $143.26M | $170.66M | $139.05M | $124.72M | $121.02M | $158.97M |
| Free cash flow | $359.34M | $320.25M | $218.81M | $395.30M | $675.44M | $203.15M | $36.75M | $376.97M | $671.36M | $674.12M | -$255.85M | $326.23M |
Frequently Asked Questions About DVA
What is DaVita HealthCare Partners' annual revenue?
DaVita HealthCare Partners reported revenue of $13.64B for the fiscal year ended Dec 31, 2025.
How fast is DaVita HealthCare Partners' revenue growing?
Revenue was up 6.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.5%.
Is DaVita HealthCare Partners profitable?
Yes. DaVita HealthCare Partners reported net income of $1.08B for the fiscal year ended Dec 31, 2025, with a net margin of 7.9%.
How much free cash flow does DVA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.89B minus capital expenditures of $575.86M produced free cash flow of $1.31B.
How much debt does DaVita HealthCare Partners have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $10.16B, short-term debt of $109.20M and cash and equivalents of $676.44M.
DVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors